Vestal Labs

Vestal is a biotechnology company pioneering a new class of small molecule therapeutics that leverage the body's natural autophagy pathway to degrade disease-causing proteins and other cellular components. Founded by leading scientists in RNA structure and protein degradation, the company's platform identifies novel targets and mechanisms for selective degradation, particularly those inaccessible by traditional ubiquitin-proteasome system (UPS)-based degraders like PROTACs. Vestal's approach has broad potential applications in oncology, neurodegeneration, and immunology, where it aims to address "undruggable" targets such as protein aggregates and damaged organelles. The company is currently in the pre-clinical stage, supported by top-tier life science investors.